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Introduction
The acquired immune deficiency syndrome (AIDS) is the manifestation of cellular immunodeficiency caused by the blood-borne virus, human immunodeficiency virus (HIV). It is one of the most important communicable diseases and its prevalence is rising. This article highlights common HIVrelated issues relevant to the ICU physician.
Background
HIV-1 and HIV-2 belong to the Lentivirus genus of the family Retroviridae, which carry their viral genes in RNA form. The virus uses the enzyme reverse transcriptase to synthesise DNA when the host cell becomes infected with either variant, producing a similar clinical syndrome. HIV-2 is endemic in West Africa, while HIV-1 is responsible for the global pandemic of AIDS. HIV-1 has an affinity for mononuclear cells leading to destruction of macrophages and T-lymphocytes. The main target is the helper T-lymphocyte, with the resulting defect in cellular immunity exposing patients to unusual opportunistic infections that are often considered difficult to treat.
A changing pattern of ICU referral
In 2007, the prevalence of HIV was approximately 77,400, with 7,734 new diagnoses of HIV made by the end of the year. 1 The widespread use of prophylaxis for Pneumocystis jirovecii (formerly Pneumocystis carinii -PCP) and the introduction of antiretroviral therapy have resulted in a decline in opportunistic infections, and death rates from HIV/AIDS remain comparatively constant (see Figure 1 ). 2 Patterns of referral to the ICU have changed in parallel with the advances in treatment. Historically, HIV was considered incurable and therefore ICU admission rates were low. 3 With the introduction of adjuvant corticosteroids in the late 1980s for the treatment of Pneumocystis jirovecii pneumonia, mortality fell. New optimism that ICU may have a role in the treatment of this patient group has seen admission rates increase during the last decade. As HAART has reduced opportunistic infection rates, there has been an evolution from HIV-associated to non-HIVassociated ICU admissions.
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Aetiology of ICU admission in HIV-positive patients Respiratory
Lower respiratory tract infection remains the most common reason for ICU admission in these patients. Historically, PCP accounted for a huge burden of disease (see Table 1 ). 4 Today, anti-retroviral therapy and primary prophylaxis against Pneumocystis jirovecii infection have made this a less common respiratory pathogen, but it still accounts for the majority of respiratory ICU admissions. Infection results in acute interstitial pneumonitis. Symptoms of shortness of breath, dry cough and fever may be preceded by malaise and weight loss with profound oxygen desaturation on exertion. The chest X-ray may appear normal or show classical peri-hilar interstitial 'ground glass' shadowing (see Figure 2 ). Occasionally, there may be localised consolidation or upper zone shadowing which resemble radiographic findings in pulmonary tuberculosis.
Bronchial lavage can be used for microscopy and silver staining for diagnosis. It is important in neutropaenic patients to exclude disseminated fungal infection, histoplasmosis, coccidioidomycosis and invasive Aspergillus fumigatus infection. Immunofluorescence techniques using monoclonal antibodies or DNA amplification by PCR are often required to confirm the diagnosis. As much as 20% of PCP infection is complicated by pulmonary bacterial infection. 3 Intense fibrogenesis occurs, further impairing gas exchange and reducing lung compliance. The need for mechanical ventilation and/or the development of pneumothorax are considered poor prognostic factors in patients with Pneumocystis jirovecii pneumonia. 3 In the UK, Pneumocystis jirovecii pneumonia has a mortality rate of 31% in ICU. 5 High dose co-trimoxazole is considered first line treatment, from which 40% of patients get adverse effects including rash, neutropaenia and fever. Second line therapy is pentamidine and clindamycin. Primaquine or dapsone with trimethoprim should be reserved for those intolerant to first and second line agents. A short course of concomitant high dose steroid should be considered if arterial oxygen tension is <9.3 kPa, as steroids have been shown to reduce morbidity and mortality. 6 Other pathogens such as Streptococcus pneumoniae and Haemophilus influenzae should be considered in HIV-positive patients, especially when the CD4 lymphocyte count is more than 200/µL. HIV-associated lymphocytic interstitial pneumonitis and bronchiolitis obliterans organising pneumonia (BOOP) are rare pathologies but must be considered when a patient fails to respond to treatment of common pathogens.
Globally, tuberculosis remains the most frequent lifethreatening opportunistic infection in AIDS, and HIV coinfection should be excluded if the patient is admitted with a diagnosis of TB. Mycobacterial disease confined to the lungs is rare in HIV-positive patients and is usually seen in conjunction with extra-pulmonary manifestations. Current recommendations are that treatment of HIV infection with HAART should begin as soon as possible in those with CD4 counts of less than 350/µL. 7 In those with higher counts, the institution of HAART is at the clinician' s discretion. Combination antibiotic therapy with three or four drugs is considered first line (isoniazid, rifampicin, pyrazinamide and ethambutol). There is significant drug toxicity and interaction with these combined regimes that make management difficult. The low virulence Mycobacterium avium complex (MAC) is more common in the developed world and affects those with CD4 counts less than 50/µL. Asthma and emphysema are common reasons for admission, implying that HIV-infected patients are living longer and succumbing to non-HIV related pathologies. 8
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Neurological
Pathology of the nervous system is the second leading cause for ICU admission, comprising up to 27% of admissions. 9 The introduction of HAART has not had a dramatic effect on inhospital mortality for HIV-positive patients suffering from primary neurological disease. 10 In the immunocompromised patient, cerebral toxoplasmosis is common (see Figure 3 ). It results in focal cerebral lesions, often presenting sub-acutely with focal neurological signs, confusion, seizures, fever and a reduced conscious level. A brain biopsy aids in differentiating between other possible aetiologies (cerebral abscess, cryptococcoma, tuberculoma, neurosyphilis and progressive multifocal leucoencephalopathy), while serum antibody testing provides a less invasive although less sensitive alternative. First line treatment is with sulfadiazine and pyrimethamine, but the incidence of adverse drug reactions is high. The use of corticosteroids to reduce cerebral oedema remains controversial.
CNS infection with Cryptococcus neoformans may be nonspecific in its presentation, with headache, mild fever and vomiting being common symptoms. Cryptococci are seen in the cerebrospinal fluid (CSF) on India ink staining, with no other abnormalities of CSF present. The combination of liposomal amphotericin B and flucytosine is the preferred treatment. Non-Hodgkin' s lymphoma is a common manifestation of CNS HIV
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Class of drug Action Examples
Nucleoside reverse Inhibit reverse transcription by being Zidovudine transcriptase inhibitors (NRTI) incorporated into the newly synthesised Lamivudine viral DNA and preventing its further elongation. Tenofovir
Non-nucleoside reverse Inhibit reserve transcriptase directly by Efavirenz transcriptase inhibitors (NNRTI) binding to the enzyme and interfering Nevirapine with its function.
Protease inhibitors (PI)
Target viral assembly by inhibiting the activity of protease. Ritonavir Atazanavir
Synergistic enhancers
When taken concurrently with antiretroviral drugs Ritonavir they enhance the effect of one or more of those drugs.
Lopinavir (Kaletra)
Fusion inhibitors
Interfere with binding, fusion and entry of HIV-1 to Enfuvirtide the host cell by blocking one of several targets.
Integrase inhibitors
Inhibit the enzyme integrase, which is responsible for Raltegravir integration of viral DNA into the DNA of the infected cell. disease that presents similarly to any space-occupying lesion. It responds poorly to radio-or chemotherapy and prognosis is often poor. Progressive leucoencephalopathy, HIV encephalopathy, cytomegalovirus retinitis and other ocular syndromes are important pathologies in the HIV-positive patient, but less likely to lead to ICU admission.
Sepsis
Severe sepsis results in substantial morbidity and mortality, accounting for approximately 15% of diagnoses in HIV-positive patients admitted to ICU. 8 Mortality from sepsis in HIVpositive patients is increased compared to those without HIV/ AIDS. 11 Pyrexia of unknown origin (PUO) should not be attributed to HIV infection per se, although occult tumour disease (Kaposi' s sarcoma), opportunistic infection and drug fevers should also be considered. Patients should be aggressively investigated with multiple blood cultures and treated with appropriate early antibiotic therapy, fluid resuscitation and organ support.
Antiretroviral therapy in the ICU
Historically, HAART regimens were based on monotherapy. Today, combination therapy has been shown to be superior in terms of reduction in plasma HIV-RNA levels. Multi-drug dosing approaches are also more efficient in delaying the emergence of resistance. The timing of initiation of HAART remains debatable, although the Medical Research Council SPARTAC trial is expected to provide initial results this year. Currently, it is initiated before the CD4 count falls below 350/µL persistently, with the development of any AIDSdefining illness or in the presence of neurological involvement. 12 Inhibitors of HIV reverse transcriptase and of HIV protease are the most widely developed agents. However, fusion and integrase inhibitors are being used increasingly. HAART regimens usually consist of a combination of three or four drugs from a number of different classes (see Table 2 ).
The use of HAART in the ICU presents distinct challenges in terms of drug delivery, dosage, interactions, resistance and associated toxic effects. 13 Most agents are formulated for oral administration and only the nucleoside reverse transcriptase inhibitor (NRTI) zidovudine can be administered intravenously. 14 There is little data on the absorption of antiretroviral agents when given via gastric or jejunal feeding tubes, and erratic gastrointestinal absorption can lead to drug resistance. HAART interactions with agents commonly used in ICU may contraindicate their use (see Table 3 ). This is especially true for non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors, both of which inhibit cytochrome P450 3A4 and so may affect metabolism of drugs such as midazolam and opiates. 13, 15 HAART drug therapy can in itself be life-threatening. 16 Lactic acidosis syndrome is associated with the NRTIs, possibly caused by their toxic effects on mitochondrial function. Treatment is supportive after withdrawal of the offending agent. Pancreatitis, nephrotoxicity and acute renal failure are common (see Table 4 ).
The immune reconstitution inflammatory syndrome (IRIS) is particular to HAART. It is a life-threatening reaction usually seen days to weeks after the initiation of HAART and is thought to result from an exuberant inflammatory response in the presence of particular pathogens, commonly latent M. avium complex. 17 hypoxaemia, an increase in radiographic infiltrate and adenomegalies. 18 The initiation of HAART in the ICU remains controversial with studies showing both improved outcome with and without its introduction. 5, 19, 20 Factors predicting survival for HIV-positive patients admitted to ICU include admission with a non-AIDS-associated diagnosis, low APACHE-2 score and high serum albumin. 3 Commonly cited causes of increased mortality are shown in Table 5 . Improvements in survival may owe more to advances in general ICU management than advances in HIV pharmacotherapy. For example, low volume tidal ventilation in HIV-infected patients with acute lung injury and respiratory failure is associated with a significantly reduced mortality. 21
Conclusions
HIV/AIDS has become an important communicable disease and public health issue both in the UK and worldwide. In the last 20 years, the emphasis has shifted from AIDS being an incurable disease to it being a chronic illness with a nearnormal life expectancy. Likewise, the epidemiology of patients admitted to the ICU has evolved, survival rates have improved and expectations have risen.
Early diagnosis and pharmacovigilance are important in maintaining health, while the role of HAART during critical illness is less clear. HIV should not be viewed as a barrier for entry to the ICU, as it is clear that the pace of change in management will undoubtedly lead to a brighter future for these patients.
